Estramustine Usage After Docetaksel in Castration Resistance in Prostate Cancer
| Autor: | Mustafa Yildirim |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: | |
| Zdroj: | Journal of Clinical and Analytical Medicine, Vol 4, Iss 139, Pp 437-439 (2013) |
| ISSN: | 1309-2014 1309-0720 |
| Popis: | Due to knowledge about molecular mechanisms of prostate cancer new agents have joined the treatment protocols of castration-resistant prostate cancer in recent years. Complications such as neutropenia, fatigue, gastrointestinal symptoms and neuropathy may occur depending on these therapy models. Estramustin is known as an orally used drug with few adverse effects in treatment of prostate cancer for a long time. In this article we aim to present the use of estramustin in a patient with progression after docataxel and discuss the effect of long-term use of estramustin in survival without progression and to emphasize that it can be an alternative treatment modality in this stage of prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|